Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO Pharmaceutical Import Records from India — 3 Products, $1.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO — Pharmaceutical Importer Profile (2026) | 3 Products, $1.7M Trade | TransData Nexus

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO

Pharmaceutical Importer · Netherlands · Diabetes & Endocrine Focus · $1.7M Total Trade · DGFT Verified

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO is a pharmaceutical importer based in Netherlands with a total trade value of $1.7M across 3 products in 3 therapeutic categories. Based on 55 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO sources from 1 verified Indian supplier, with Mylan Laboratories Limited accounting for 100.0% of imports.

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO — Import Portfolio & Supplier Network

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$6.8M	257	100.0%

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO sources from 1 verified Indian supplier across 165 distinct formulations. The sourcing is highly concentrated — Mylan Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Sita/metf TAB 50MG/1000MG 60bl fr	$800.0K	16
Metf/sita TAB 1000/50MG 56bl pt	$300.0K	6
Metf/sita TAB 850/50MG 56bl pt	$267.5K	6
Sitagliptine viatris 50 MG 28bl TAB	$167.7K	4
Sertraline TAB 100MG	$150.0K	3
Atorvastatin TAB 40MG 90bt nl	$150.0K	3
Atorvastatin TAB 20MG 30bl fr	$108.6K	3
Sitagliptin TAB 50MG 28bl it	$101.6K	3
Sitagliptin TAB 100MG 28bl fr	$100.0K	2
Lorstat TAB 40MG 500 bot	$100.0K	2
Alfuzosin TAB pr 10MG	$100.0K	2
Sertraline TAB 50MG	$100.0K	2
Atorvastatin TAB 10MG 90bl fr	$100.0K	2
Atorvastatin TAB 20MG 90bl fr	$100.0K	2
Mycophenolate TAB 500MG 50bl fr	$100.0K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sitagliptin	Diabetes & Endocrine	$1.2M	36	1.6%	17
2	Febuxostat	Lipid & Metabolism	$414.0K	16	0.8%	17
3	Warfarin	Cardiovascular	$95.4K	3	1.3%	13

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO imports 3 pharmaceutical products across 3 categories into Netherlands totaling $1.7M.

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO is a pharmaceutical importer based in the Netherlands, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a buyer, sourcing a range of pharmaceutical products to meet the demands of the Dutch market. While specific details about its headquarters and parent company are not publicly available, its role in the Netherlands pharmaceutical distribution network is significant, focusing on the importation and distribution of generic medications.

2Distribution Network

The distribution network specifics of Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO are not publicly disclosed. However, given the company's focus on importing finished pharmaceutical formulations from India, it is likely that it collaborates with established logistics providers to ensure efficient delivery within the Netherlands. The Netherlands' strategic location and advanced logistics infrastructure, including proximity to major ports and airports, facilitate the efficient distribution of pharmaceutical products throughout the country.

3Industry Role

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from India. Its role in the Netherlands pharmaceutical supply chain involves importing generic medications to meet domestic demand. The company's focus on finished formulations indicates a specialization in the distribution of ready-to-use pharmaceutical products, catering to various therapeutic areas.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy reveals a high concentration on a single supplier, MYLAN LABORATORIES LIMITED, which accounts for 100% of its imports from India. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments and the substantial total import value suggest a stable and long-term relationship between Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO and MYLAN LABORATORIES LIMITED. The company's portfolio concentration, with the top five products comprising 100% of its imports, further indicates a focused sourcing approach.

2Supply Chain Resilience

The resilience of Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's supply chain is closely tied to its exclusive reliance on MYLAN LABORATORIES LIMITED. This singular sourcing strategy may limit the company's ability to mitigate risks associated with supply chain disruptions. The lack of publicly available information on backup suppliers and formulation diversity suggests potential vulnerabilities. Additionally, the company's exposure to specific shipping routes and its compliance with regulatory standards are not detailed, which are critical factors in assessing overall supply chain resilience.

Strategic Implications

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the Medicines Evaluation Board (MEB) is the primary regulatory authority overseeing the authorization and supervision of medicinal products. The Medicines Act (Geneesmiddelenwet) serves as the key legislation governing pharmaceutical imports, ensuring that all medicinal products meet safety, efficacy, and quality standards. For Indian generics, obtaining a marketing authorization from the MEB is essential for entry into the Dutch market. This process involves demonstrating that the generic product is interchangeable with the Dutch reference medicinal product, ensuring no differences in efficacy and safety. (english.cbg-meb.nl)

2Import Licensing & GMP

Importers of medicinal products into the Netherlands must obtain a pharmaceutical permit from the Dutch Ministry of Health, Welfare, and Sport (VWS). This permit is mandatory for entities involved in the wholesale or packaging of medicines. Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards. The MEB recognizes GMP certificates from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers hold valid GMP certifications from these recognized bodies to maintain compliance with Dutch regulations. (business.gov.nl)

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's product strategy focuses on therapeutic areas with high demand in the Netherlands. The company's imports are predominantly in the Diabetes & Endocrine category (69.9%), followed by Lipid & Metabolism (24.5%), and Cardiovascular (5.6%). This focus aligns with the growing prevalence of lifestyle-related diseases in the Netherlands, such as diabetes and cardiovascular conditions. The substantial import value of Sitagliptin ($1.2M) and Febuxostat ($414K) indicates a strategic emphasis on these high-demand medications.

2Sourcing Profile

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's sourcing strategy is centered on generic drugs, primarily sourced from India. The company's preference for finished pharmaceutical formulations suggests a focus on ready-to-use products that meet Dutch regulatory standards. India's robust pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a reliable source for these products. The company's exclusive reliance on MYLAN LABORATORIES LIMITED for its imports indicates a strategic partnership aimed at ensuring consistent quality and supply.

3Market Positioning

Seller's Guide — How to Become a Supplier to Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to engage with Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO, given the company's exclusive reliance on MYLAN LABORATORIES LIMITED. Introducing alternative suppliers could provide the company with options to diversify its sourcing and mitigate potential supply chain risks. However, the company's concentrated product portfolio, with the top five products comprising 100% of its imports, suggests that any new supplier would need to offer products that align with the company's existing therapeutic focus.

2Requirements & Qualifications

Indian exporters aiming to supply Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO and the broader Netherlands market must ensure compliance with Dutch and EU regulations. This includes obtaining marketing authorizations from the Medicines Evaluation Board (MEB) and ensuring that products meet Dutch safety, efficacy, and quality standards. Additionally, products must comply with Good Manufacturing Practice (GMP) standards recognized by the MEB, such as EU GMP, WHO GMP, or PIC/S certifications. Proper labeling in Dutch and adherence to serialization mandates are also essential. (english.cbg-meb.nl)

How to Approach

Frequently Asked Questions — Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO

What products does Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO import from India?

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO imports 3 pharmaceutical products across 3 categories. Top imports: Sitagliptin ($1.2M), Febuxostat ($414.0K), Warfarin ($95.4K).

Who supplies pharmaceuticals to Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO from India?

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO sources from 1 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (100.0% of imports, $6.8M).

What is Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's total pharmaceutical import value?

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO's total pharmaceutical import value from India is $1.7M, based on 55 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO focus on?

Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO imports across 3 categories. The largest: Diabetes & Endocrine (69.9%), Lipid & Metabolism (24.5%), Cardiovascular (5.6%).

Get Full Xxlanxxrelxxd Lxxitexx Nexxnhaxxcouxx Mxxahixx RO Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.